Google Inc vs Novavax Inc — how do they compare? Google Inc trades at $371.16 (market cap $4.52T), while Novavax Inc trades at $8.23 (market cap $1.39B). The key difference: Google Inc is far larger — about 3251.8× Novavax Inc's market cap, and Google Inc pays a 0.24% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| GOOG | NVAX | |
|---|---|---|
Market Cap | $4.52T | $1.39B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $11.19 |
52-Week Low | $183.77 | $6.22 |
Enterprise Value | $4.49T | $890.94M |
Dividend Yield | 0.24% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.
Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →